Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Vicore Pharma Holding ABNASDAQ: VCRE

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue declines year over year

Q2 FY2026 revenue of SEK 228.25K fell 86.9% year over year, behind the -57.1% change in trailing-twelve-month revenue. Sequentially, it fell 62.1% from the prior quarter.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 9 analysts of SEK 534.04K (-86.0%) for the fiscal year ending Dec 2026, a step up from the -96.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
SEK 228.25K-62.1% QoQ
Last fiscal yearDec 2025
SEK 3.82M-96.5% YoY
LTMJun 2026
SEK 1.33M-57.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-86.9%+32.3%+119.2 pp
1 year-96.5%-86.0%+10.5 pp
3-year CAGR—-53.7%—
5-year CAGR-34.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

SEK · from the income statement

Latest · FY2025
3.82M SEK
Year-over-year change
-96.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -57.1% is the lowest of 2, against a peer median of +2233.6%.
VCRE Competitors
Revenue for VCRE and competitors
Company Period LTM YoY 3-year CAGR
LQDALiquidia CorporationLTM Jun 2026$450.91M USD+2233.6%+115.0%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 1.33M SEK-57.1%—
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding VCRE) —+2233.6%+115.0%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000109.35M3.82M
Cost of Revenue3.58M0000
Gross Profit(3.58M)00109.35M3.82M
Gross Margin———100.0%100.0%
Research & Development30.05M249.97M276.29M249.26M390.35M
Selling, General & Admin2.39M37.53M44.6M50.44M67.91M
Operating Expenses32.59M290.73M321.51M299.71M458.26M
Depreciation & Amortization371.33K3.61M3.42M2.24M0
EBITDA(32.07M)(285.19M)(307.9M)(166.64M)(477.41M)
EBITDA Margin———-152.4%-12507.6%
Operating Income(32.59M)(290.73M)(321.51M)(190.36M)(454.45M)
Operating Margin———-174.1%-11905.8%
Interest Income70.2K913K10.54M21.08M23.89M
Interest Expense08K2K8K60K
Other Income / Expenses(211.92K)1.92M10.18M21.47M(23.03M)
Income Before Tax(32.8M)(288.81M)(311.33M)(168.89M)(477.47M)
Pre-Tax Margin———-154.5%-12509.1%
Income Tax Expense(252.7K)(384K)(384K)(256K)0
Net Income(294.97M)(288.42M)(310.94M)(168.63M)(477.47M)
Net Margin———-154.2%-12509.1%
EPS (Basic)(0.47)(38.82)(31.80)(12.30)(19.90)
EPS (Diluted)(0.47)(38.82)(31.80)(12.30)(19.90)
Weighted Avg Shares69.68M7.42M9.66M13.68M23.99M
Weighted Avg Shares (Diluted)69.68M7.42M9.66M13.68M23.99M

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.